18.08 07:44 | dpa-AFX: Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out |
15.08 06:03 | dpa-AFX: Gilead Sciences' Livdelzi Receives Accelerated FDA Approval For Primary Biliary Cholangitis |
11.08 17:21 | dpa-AFX: Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray |
09.08 22:06 | MÄRKTE USA/Aktien nach Vortagsrally weiter aufwärts |
09.08 19:02 | MÄRKTE USA/Ruhe nach Vortagesrally - Eli Lilly erneut sehr fest |
09.08 18:56 | MÄRKTE USA/Ruhe nach Vortagesrally - Eli Lilly erneut sehr fest |
09.08 16:02 | MÄRKTE USA/Geopolitik sorgt für Vorsicht |
09.08 15:04 | MÄRKTE USA/Wall Street mit Geopolitik im Minus gesehen |
08.08 22:44 | dpa-AFX: ROUNDUP: Gilead Sciences Q2 Profit Rises, Revises Full-year Guidance |
08.08 22:33 | dpa-AFX: Gilead Sciences Inc. Bottom Line Rises In Q2, But Misses Estimates |
08.08 22:17 | dpa-AFX: *GILEAD SCIENCES Q2 EPS $1.29 VS. $0.83 YEAR AGO |
08.08 22:17 | dpa-AFX: *GILEAD SCIENCES Q2 NET INCOME TO CO. $1.61 BLN VS. $1.05 BLN PRIOR YEAR |
08.08 22:17 | dpa-AFX: *GILEAD SCIENCES Q2 REVENUES $6.95 BLN VS. $6.60 BLN LAST YEAR |
08.08 12:01 | dpa-AFX: Gilead Sciences Q2 24 Earnings Conference Call At 4:30 PM ET |
30.07 10:19 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
29.07 10:15 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
25.07 16:40 | dpa-AFX: Gilead's New Data Reinforce Biktarvy As Long-Term HIV Treatment Option; Stock Up |
25.07 15:22 | dpa-AFX: *GILEAD: NEW 5-YEAR DATA REINFORCE BIKTARVY AS LONG-TERM HIV TREATMENT OPTION |
24.07 20:48 | dpa-AFX: Gilead's Twice-yearly Injection Offers 100% Protection Against HIV In Women: Study |
24.07 12:08 | dpa-AFX: Gilead Sciences Reports New Efficacy, Safety Results From Lenacapavir Trial For HIV Prevention |
|